[en] The use of accelerator-produced radioisotopes (NARM), particularly in medicine, is growing rapidly. One NARM radioisotope, ²²⁶Ra, is one of the most hazardous of radioactive materials, and ²²⁶Ra is used by about ¹/₅ of all radioactive material users. Also, there are about 85,000 medical treatments using ²²⁶Ra each year. All of the 25 Agreement States and 5 non-Agreement States have licensing programs covering NARM users. The Agreement States' programs for regulating NARM are comparable to their programs for regulating byproduct, source, and special nuclear materials under agreements with NRC. But there are 7 states who exercise no regulatory control over NARM users, and the remaining States have control programs which are variable in scope. There are no national, uniformly applied programs to regulate the design, fabrication and quality of sources and devices containing NARM or consumer products containing NARM which are distributed in interstate commerce. Naturally occurring radioactive material (except source material) associated with the nuclear fuel cycle is only partially subject to NRC regulation, i.e., when it is associated with source or special nuclear material being used under an active NRC license. The Task Force recommends that the NRC seek legislative authority to regulate naturally occurring and accelerator-produced radioactive materials for the reason that these materials present significant radiation exposure potential and present controls are fragmentary and non-uniform at both the State and Federal level